SCRI at the 2024 ASCO® Annual Meeting

For the first time at the 2023 ASCO® Annual Meeting, colleagues from across newly combined SCRI network will share the cancer research insights with oncology leaders from around the globe.

SCRI at the 2023 ASCO® Annual Meeting

135+
Abstracts & Presentations
 
64
Early-Phase Studies Featured
 
82
Authors Across SCRI
 
77
Sponsors Represented Through Selected Abstracts & Presentations
 
 

Experts from across SCRI’s network will discuss the latest research findings that cover a variety of topics including…

Breast Cancer:

Erika Hamilton
Erika Hamilton, MD, SCRI at Tennessee Oncology, will give two oral presentations – “Efficacy and Safety Results by Age in monarchE: Adjuvant Abemaciclib Combined with Endocrine Therapy in Patients with HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer” on June 2 at 2:45 p.m. CDT in Hall D1 and “A Phase 2 Study of HER3-DXd in Patients with Metastatic Breast Cancer” on June 5 at 11:30 a.m. CDT in Hall B1.
 
Denise Yardley
Denise Yardley, MD, SCRI at Tennessee Oncology, contributed to research featured in the oral presentation, “Ribociclib and Endocrine Therapy as Adjuvant Treatment in Patients with HR+/HER2− Early Breast Cancer: Primary Results from the Phase III NATALEE Trial,” which will take place on June 2 at 2:45 p.m. CDT in Hall D1.
 

Genitourinary Cancer:

Thomas Huston
Thomas Hutson, DO, PharmD, SCRI at Texas Oncology I The US Oncology Network, will deliver “Final Prespecified Overall Survival Analysis of CLEAR: 4-Year Follow-Up of Lenvatinib Plus Pembrolizumab vs Sunitinib in Patients with Advanced Renal Cell Carcinoma” in an oral presentation on June 5 at 11:30 a.m. CDT in Hall D1.
 

Lung Cancer:

Melissa Johnson
Melissa Johnson, MD, SCRI at Tennessee Oncology, will present “ARC-7: Randomized Phase 2 Study of Domvanalimab + Zimberelimab Etrumadenant vs Zimberelimab in First-Line, Metastatic, PD-L1-High Non-Small Cell Lung Cancer” in the ASCO Plenary Series: Rapid Abstract Updates on June 3 at 12:30 p.m. CDT in the Arie Crown Theater. Dr. Johnson also co-authored research that will be featured in the oral presentation, “First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6 –Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer,” on June 5 at 8 a.m. CDT in Hall D2.
 

Melanoma/Skin Cancer:

Meredith McKean
Meredith McKean, MD, MPH, SCRI at Tennessee Oncology, participated in research that will be featured in the oral presentation, “Distant Metastasis-Free Survival Results from the Randomized, Phase 2 mRNA-4157-P201/KEYNOTE-942 Trial,” on June 5 at 3 p.m. CDT in Hall D1.
 
Access SCRI’s Full List of Abstracts & Presentations
 

We Look Forward to Seeing You!

We hope to see you in person at the 2023 ASCO® Annual Meeting. Visit SCRI at Booth #13033 to speak with our colleagues and research leaders.

Learn More About the Power of The SCRI Network from Our Leadership Team

top